Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active Thyroid Eye Disease (TED). Batoclimab, subcutaneous formulation, offers the potential for at-home administration, ...

KORU Medical Systems (NASDAQ:KRMD – Get Free Report) is expected to issue its quarterly earnings data after the market closes on Wednesday, March 12th. Analysts expect the company to announce earnings ...

What is Guillain-Barré syndrome? Guillain-Barré syndrome (GBS) is also called acute inflammatory demyelinating polyradiculoneuropathy (AIDP). It's a neurological disorder in which the body's immune ...

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART HytrulogMG patients on VYVGART achieve rapid, substantial, and sustained efficacy ...

Bagnasco has received speaker’s honoraria and advisory board membership from AstraZeneca, Chiesi, Firma, GSK, Novartis, Menarini, Sanofi, and Zambon. Berti has received funding from GSK for advisory ...

Trying to balance chronic conditions and work has led to negative consequences, with 36 percent of those with chronic conditions saying they have skipped medical appointments or delayed getting ...

The GBS | CIDP Foundation International has unveiled survey data that paints a sobering picture of the physical, social, and financial challenges faced by individuals with Guillain-Barré Syndrome ...

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

professor of neurology at the University of Minnesota Medical School and head of the GBS | CIDP Foundation International's Global Medical Advisory Board. "Our new report mapping the patient ...

Much more research is needed to fully elucidate the pathophysiology of CIDP, and whether peritoneal dialysis in any ways aggravates or triggers this disorder. Dr. Ryner Lai is a medical writer who is ...

That's also why we're advancing empasiprubart in CIDP despite the fact that we printed the highest response rate average 70%. There is a 30% of patients which have a medical need and were not ...

“We are extremely proud of the initial launch efforts of VYVGART Hytrulo in CIDP, where the strength of our data has driven early positive feedback from both patients and physicians. This execution ...